Pace Payment Systems Sold to i3 Verticals

We represented Pace Payment Systems, Inc. in its sale to i3 Verticals, Inc. for $52.7 million, plus an earnout payment of up to $20 million based on the achievement of certain metrics during periods following the closing. This transaction marked i3 Verticals’ fourth acquisition this year and deepened its reach within the public sector vertical.

The deal team representing Pace was led by corporate attorneys Kevin Douglas and John Fuller and included corporate attorneys Taylor Wirth, Mark Buente and David Marshburn. Firm attorneys Bob Brewer and Chelsea Harrison advised on intellectual property matters; Todd Ervin counseled on tax issues; Doug Dahl and Noah Black on employee benefit aspects; Felix Dowsley on debt financing matters; and Steve Taylor on insurance matters.

Pace was a private company which markets, distributes and sells payment processing products (including software products) and services, primarily through integrated partnerships in the Public Sector and Education verticals.

i3 Verticals is an NYSE-listed company which delivers seamless integrated payment and software solutions to small- and medium-sized businesses (SMBs) and organizations in strategic vertical markets. Since commencing operations, i3 Verticals has built a broad suite of payment and software solutions that address the specific needs of SMBs and other organizations in its strategic vertical markets.

You Also May Be Interested In:

  • We represented ALS Education, Inc., an education dropout prevention and recovery program, in the sale of its charter school management...
    Client Type: Private Company
  • Lead Counsel to POINT Biopharma Inc. in connection with its proposed SPAC business combination with Therapeutics Acquisition Corp. d/b/a Research Alliance Corp. I (Nasdaq: RACA), a special purpose acquisition company, sponsored by RA Capital Management.  Upon closing, the combined company will be named POINT Biopharma Global Inc. and is expected to be listed on Nasdaq under the ticker symbol “PNT”.

    We served as lead legal counsel to POINT Biopharma Inc., a late stage biopharmaceutical company dedicated to bringing the many...
    Client Type: Private Company
  • Representation of NN, Inc. (NASDAQ: NNBR) in a new financing with J.P. Morgan, funds managed by Oaktree Capital Management, L.P., and investment funds managed by Morgan Stanley Tactical Value providing a $50 million asset-based credit line (ABL), a 5.5-year $150 million term loan, and a $65 million preferred stock issuance, respectively. Proceeds from the transaction will be used to repay the current principal balance of $70 million on its term loans due in 2022, to redeem its current $100 million outstanding preferred stock, prior to the increase in redemption premium at March 31, 2021, and pay off its fixed interest rate swap of $14 million. The transaction enables the company to strengthen its balance sheet by extending its capital structure’s maturity at an attractive blended cost of capital, allowing the company financial flexibility to continue its current business transformation efforts.

    We represented NN, Inc. (NASDAQ: NNBR) in a new financing with J.P. Morgan, funds managed by Oaktree Capital Management, L.P., and...
    Client Type: Public Company